Literature DB >> 9506542

Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium.

R Tawil1, D A Figlewicz, R C Griggs, B Weiffenbach.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited diseases of muscle. Until recently, FSHD had received little attention because of its relatively benign course and the perception that it represented a syndrome rather than a distinct myopathy. Research interest into this disease was reignited with the demonstration of linkage of FSHD to chromosome 4q35 in 1990. Clinical and molecular genetic research in FSHD has since helped define it as a distinct clinical entity, outlined its natural history, and defined the primary molecular defect associated with the condition. FSHD is now known to be associated with large deletions of variable size on chromosome 4q35. These deletions, however, do not appear to disrupt a transcribed gene but are thought to interfere with the expression of a gene or genes located proximal to the deletions. These observations complicate the search for the FSHD gene but also imply the presence of a potentially novel molecular pathogenesis.

Entities:  

Mesh:

Year:  1998        PMID: 9506542     DOI: 10.1002/ana.410430303

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

Review 1.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

2.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

3.  Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.

Authors:  David B Olsen; Peter Gideon; Tina Dysgaard Jeppesen; John Vissing
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

Review 4.  Ophthalmic manifestations of inherited neurodegenerative disorders.

Authors:  Hannah M Kersten; Richard H Roxburgh; Helen V Danesh-Meyer
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

5.  Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Authors:  Joerg-Patrick Stübgen; Annette Stipp
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

6.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.

Authors:  Manjusha Dixit; Eugénie Ansseau; Alexandra Tassin; Sara Winokur; Rongye Shi; Hong Qian; Sébastien Sauvage; Christel Mattéotti; Anne M van Acker; Oberdan Leo; Denise Figlewicz; Marietta Barro; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Yi-Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

Review 7.  The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.

Authors:  Daphne Selvaggia Cabianca; Davide Gabellini
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

Review 8.  Drug treatment for facioscapulohumeral muscular dystrophy.

Authors:  M R Rose; R Tawil
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 9.  The role of genetics in the establishment and maintenance of the epigenome.

Authors:  Covadonga Huidobro; Agustin F Fernandez; Mario F Fraga
Journal:  Cell Mol Life Sci       Date:  2013-03-10       Impact factor: 9.261

10.  The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy.

Authors:  Alexandre Ottaviani; Sylvie Rival-Gervier; Amina Boussouar; Andrea M Foerster; Delphine Rondier; Sabrina Sacconi; Claude Desnuelle; Eric Gilson; Frédérique Magdinier
Journal:  PLoS Genet       Date:  2009-02-27       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.